FDA Approves Combo Tx for Intermediate, Poor-Risk Advanced Kidney Cancer
The approvals for nivolumab and ipilimumab were based on CheckMate 214, a randomized open-label trial.
The approvals for nivolumab and ipilimumab were based on CheckMate 214, a randomized open-label trial.
Approval provides for treatment in the first-line setting.
Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.